FDA reviews BPC-157, TB-500 and other peptides favored by RFK Jr.

Key Points:

• Health advisers are meeting at the FDA to review seven popular peptides, substances promoted for wellness but lacking strong evidence of safety or effectiveness, amid growing public interest and support from Health Secretary Robert F. Kennedy Jr.
• FDA scientists and many medical experts express concerns over insufficient data on peptide safety, risks of contamination, allergic reactions, and quality control, recommending against their wider availability through compounding pharmacies.
• The advisory panel reviewing peptides includes members with financial ties to the peptide industry, raising concerns about conflicts of interest, although additional independent experts have been added to the group.
• Public comments largely support peptide access, with advocates arguing for regulated pharmacy availability as a safer alternative to unregulated markets, while the FDA considers these views alongside scientific assessments.
• The FDA’s final decision may involve a temporary policy allowing pharmacies to compound these peptides without enforcement actions, but formal approval would require lengthy regulatory processes; this outcome aligns with Health Secretary Kennedy’s agenda to ease restrictions.